New obesity pill shows promise in early Fat-Burning study

NCT ID NCT06824051

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested an oral drug called orforglipron in 120 adults with obesity or overweight (but without diabetes). The goal was to see how it changes body fat compared to a placebo over about 8 months. Researchers measured fat around organs, appetite, and weight. This is a first step to see if the drug might become a future weight-loss treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: orforglipron (an oral drug)
What this could lead to: If it works, this could point toward a new daily pill to help people with obesity or overweight lose body fat.
What could go wrong: This is a very early Phase 1 study with only 120 people, so results may not hold up in larger trials. The drug may cause side effects or fail to reduce fat significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

Axis

Dilworth, Minnesota, 56529, United States
Clinical Pharmacology of Miami

Miami, Florida, 33172, United States
Endeavor Clinical Trials

San Antonio, Texas, 78240, United States
Ohio Clinical Trials

Columbus, Ohio, 43212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.